Accessibility Menu
IceCure Medical logo

IceCure Medical(NASDAQ) ICCM

Market Cap$7.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-26%
5 Year-99%
1 Year-93%
1 Month-31%
$2.21
-2.21%
-0.05Today
After hours$2.22+$0.01 (+0.45%)
IceCure Medical last closing stock price
MetricPriceDate
Last closeUSD 2.232026-09-04
IceCure Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.04%USD 2.302026-08-28
1 month-30.53%USD 3.212026-08-05
3 month-48.91%USD 4.372026-06-05
Year to date-87.82%USD 18.302025-12-31
1 year-92.99%USD 31.802025-09-04
3 year-93.36%USD 33.602023-09-05
5 year-99.26%USD 302.102021-09-03
Since inception-26.01%USD 3.012013-11-07

IceCure Medical Financials at a Glance

Market Cap

$7.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.95M

Net Income (TTM)

-$16.88M

EPS (TTM)

-$6.57

P/E Ratio

-0.34

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$2.21

Volume

58,439

Open

$2.20

Previous Close

$2.23

Daily Range

$2.13 - $2.25

52-Week Range

$2.12 - $42.00

Estimated Earnings Date

Nov 18, 2026

ICCM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About IceCure Medical

IceCure Medical Ltd is a medical device company based in Caesarea, Israel, specializing in innovative solutions for tumor treatment through cryoablation. Founded in 2006, the company focuses on developing and marketing its primary product, the ProSense system, which offers specialized cryoablation therapy for breast tumors.

Products and Services
  • ProSense system for cryoablation therapy
  • Innovative solutions for tumor treatment
  • Research and development in medical devices
Growth Outlook
  • Market demand for non-invasive tumor treatments is increasing
  • Expansion into new markets is underway
  • Continued investment in R&D to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of 907,000, showing stability
  • Cash and cash equivalents increased to 12,034,000
  • Current ratio of 2.87 indicates strong liquidity position
IceCure Medical Ltd is positioned in the healthcare sector, specifically within the medical devices industry. The company has demonstrated a commitment to innovation, particularly in the field of cryoablation therapy, which is gaining traction as a less invasive treatment option for tumors. The ProSense system is central to IceCure's strategy, aiming to provide effective solutions for patients while addressing the growing demand for non-invasive medical treatments. The growth outlook for IceCure Medical is promising, driven by an increasing market demand for innovative tumor treatments and the company's strategic expansion into new markets. Investment in research and development remains a priority, ensuring that IceCure continues to enhance its product offerings and maintain a competitive edge. Financially, IceCure Medical has shown resilience, with a recent quarterly revenue of 907,000, reflecting stability in operations. The company's cash and cash equivalents have risen to 12,034,000, providing a solid foundation for future growth. Additionally, a current ratio of 2.87 indicates a strong liquidity position, allowing the company to meet its short-term obligations effectively. Overall, IceCure Medical Ltd presents an intriguing opportunity for potential investors interested in the medical device sector, particularly in innovative solutions for tumor treatment.
AI Generated • Aug 22, 2026

Industry

Healthcare Equipment and Supplies

Employees

69

CEO

Eyal Shamir, MBA

Headquarters

Caesarea, HA 3079504, IL

ICCM Financials

Key Financial Metrics (TTM)

Gross Margin

36.10%

Operating Margin

-556.35%

Net Income Margin

-427.67%

Return on Equity

-174.26%

Return on Capital

-162.86%

Return on Assets

-95.33%

Earnings Yield

-2.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.43M

Volume

58.44K

Avg. Volume

3.26M

Financials (TTM)

Gross Profit

$1.43M

Operating Income

-$21.96M

EBITDA

-$16.44M

Operating Cash Flow

-$16.32M

Capital Expenditure

-$69.77K

Free Cash Flow

-$16.39M

Cash & ST Invst.

$12.03M

Total Debt

$90.00K

IceCure Medical Performance Analysis

IceCure Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,085,000-25.4%
20232023-12-31USD 3,229,0004.7%
20242024-12-31USD 3,291,0001.9%
20252025-12-31USD 3,379,0002.7%
IceCure Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3061.9%
Q42025-12-3150.5%
Q12026-03-31-28.8%
Q22026-06-30-0.4%
IceCure Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -13.5032.3%
20232023-12-31USD -9.45-30.0%
20242024-12-31USD -8.86-6.2%
20252025-12-31USD -7.10-19.8%
IceCure Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.4%
Q42025-12-313.5%
Q12026-03-310.5%
Q22026-06-3016.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$907.00K

+72.8%

Gross Profit

$253.00K

+93.1%

Gross Margin

27.89%

N/A

Market Cap

$7.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$112.38K

N/A

Employees

68

N/A

Net Income

-$4.50M

-33.8%

EBITDA

-$4.35M

-31.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$12.03M

+123.6%

Total Debt

$90.00K

-96.2%

Accounts Receivable

$413.00K

-68.4%

Inventory

$2.55M

+9.3%

Long Term Debt

$21.00K

-64.4%

Short Term Debt

$69.00K

-97.0%

Return on Assets

-95.33%

N/A

Return on Invested Capital

-1.84%

N/A

Free Cash Flow

-$3.89M

-37.2%

Operating Cash Flow

-$3.88M

-37.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDCXMedicus Pharma Ltd. Common Stock
$0.17+0.88%
CTSOCytosorbents Corporation
$0.35+0.03%
TELATELA Bio, Inc.
$0.82+5.19%
PETSPetMed Express, Inc.
$1.81-2.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About ICCM

What is the current price of IceCure Medical?

IceCure Medical is trading at $2.23 per share.

What is the 52-week range for IceCure Medical?

Over the past 52 weeks, IceCure Medical has traded between $2.12 and $42.00.

How much debt does IceCure Medical have?

As of the most recent reporting period, IceCure Medical reported total debt of $90.00K.

How much cash does IceCure Medical have on hand?

IceCure Medical reported $12.03M in cash and cash equivalents in its most recent financial results.

What is IceCure Medical’s dividend yield?

IceCure Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.